BACKGROUND: Retrieval of fewer than 10 lymph nodes at axillary dissection (ALND) for breast cancer can represent anatomic variation or inadequate dissection. We postulated that despite aggressive ALND, a lower lymph node count is more frequent after neoadjuvant chemotherapy. METHODS: Patients who received neoadjuvant chemotherapy followed by ALND were compared with patients who received surgery first. All patients received a level I and II ALND at a single institution by one of the breast surgeons. The number of nodes retrieved at ALND was dichotomized into categories (< 10 and > or = 10), and compared using Fisher exact test. RESULTS: A total of 143 neoadjuvant and 170 surgery-first patients were studied. Patients treated with neoadjuvant chemotherapy were significantly more likely to have fewer than 10 lymph nodes retrieved at ALND than were the surgery-first patients (19/143 or 13% vs. 6/170 or 4%, P = .003). CONCLUSIONS: A low lymph node count is more common in patients after treatment with neoadjuvant chemotherapy and should not be assumed to represent an incomplete ALND.
BACKGROUND: Retrieval of fewer than 10 lymph nodes at axillary dissection (ALND) for breast cancer can represent anatomic variation or inadequate dissection. We postulated that despite aggressive ALND, a lower lymph node count is more frequent after neoadjuvant chemotherapy. METHODS:Patients who received neoadjuvant chemotherapy followed by ALND were compared with patients who received surgery first. All patients received a level I and II ALND at a single institution by one of the breast surgeons. The number of nodes retrieved at ALND was dichotomized into categories (< 10 and > or = 10), and compared using Fisher exact test. RESULTS: A total of 143 neoadjuvant and 170 surgery-first patients were studied. Patients treated with neoadjuvant chemotherapy were significantly more likely to have fewer than 10 lymph nodes retrieved at ALND than were the surgery-first patients (19/143 or 13% vs. 6/170 or 4%, P = .003). CONCLUSIONS: A low lymph node count is more common in patients after treatment with neoadjuvant chemotherapy and should not be assumed to represent an incomplete ALND.
Authors: Michael P O'Leary; Brian J Beckord; Kyle E Mock; Rose J Venegas; James J Yeh; Christine E Dauphine; Junko J Ozao-Choy Journal: Cancer Rep (Hoboken) Date: 2018-09-16
Authors: Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans Journal: Mod Pathol Date: 2015-07-24 Impact factor: 7.842
Authors: Ryan K Schmocker; Holly Caretta-Weyer; Jennifer M Weiss; Katie Ronk; Jeffrey Havlena; Noelle K Loconte; Marquita Decker; Maureen A Smith; Caprice C Greenberg; Heather B Neuman Journal: J Surg Oncol Date: 2014-03-18 Impact factor: 3.454
Authors: Jeeyeon Lee; Nora Jee-Young Park; Byeongju Kang; Jin Hyang Jung; Wan Wook Kim; Yee Soo Chae; Soo Jung Lee; Hye Jung Kim; Ji-Young Park; Ho Yong Park Journal: Front Surg Date: 2022-03-31
Authors: J M Noh; W Park; C-O Suh; K C Keum; Y B Kim; K H Shin; K Kim; E K Chie; S W Ha; S S Kim; S D Ahn; H S Shin; J H Kim; H-S Lee; N K Lee; S J Huh; D H Choi Journal: Br J Cancer Date: 2014-01-30 Impact factor: 7.640
Authors: Thalia Erbes; Marzenna Orlowska-Volk; Axel Zur Hausen; Gerta Rücker; Sebastian Mayer; Matthias Voigt; Juliane Farthmann; Severine Iborra; Marc Hirschfeld; Philipp T Meyer; Gerald Gitsch; Elmar Stickeler Journal: BMC Cancer Date: 2014-01-03 Impact factor: 4.430